CYSLTR1 and metabolic dysfunction-associated steatohepatitis: In the present study, we report the synthesis and the pharmacological characterization of compound 2 as the first in a class of a novel series of orally active dual CysLT1R antagonists/GPBAR1 agonists showing efficacy in a validated model of NASH.